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Summary
Natural tetracycline (TC) antibiotics were the fi rst major class of therapeutics to earn 
the distinction of ‘broad-spectrum antibiotics’ and they have been used since the 1940s 
against a wide range of both Gram-positive and Gram-negative pathogens, mycoplasmas, 
intracellular chlamydiae, rickett siae and protozoan parasites. The second generation of 
semisynthetic tetracyclines, such as minocycline and doxycycline, with improved antimi-
crobial potency, were introduced during the 1960s. Despite emerging resistance to TCs 
erupting during the 1980s, it was not until 2006, more than four decades later, that a third-
-generation TC, named tigecycline, was launched. In addition, two TC analogues, omada-
cycline and eravacycline, developed via (semi)synthetic and fully synthetic routes, respec-
tively, are at present under clinical evaluation. Interestingly, despite very productive early 
work on the isolation of a Streptomyces aureofaciens mutant strain that produced 6-demeth-
yl-7-chlortetracycline, the key intermediate in the production of second- and third-genera-
tion TCs, biosynthetic approaches in TC development have not been productive for more 
than 50 years. Relatively slow and tedious molecular biology approaches for the genetic 
manipulation of TC-producing actinobacteria, as well as an insuffi  cient understanding of 
the enzymatic mechanisms involved in TC biosynthesis have signifi cantly contributed to 
the low success of such biosynthetic engineering eff orts. However, new opportunities in 
TC drug development have arisen thanks to a signifi cant progress in the development of 
aff ordable and versatile biosynthetic engineering and synthetic biology approaches, and, 
importantly, to a much deeper understanding of TC biosynthesis, mostly gained over the 
last two decades.
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Introduction
Tetracyclines (TCs) are polyketide natural products, 
which include a number of clinically important antibacte-
rials, such as oxytetracycline (5-hydroxy-TC, OTC) and 
chlortetracycline (7-chlor-TC, CTC). TCs were the fi rst 
major class of therapeutics to earn the distinction of ‘broad -
-spectrum antibiotics’, and they have been used since the 
1940s against a wide range of both Gram-positive and Gram- 
 -negative pathogens, mycoplasmas, intracellular chlamy-
diae, rickett siae and protozoan parasites (1). The basic TC 
structure comprises four linearly fused six-membered 
carbon rings, to which diff erent functional groups are at-
tached (Fig. 1; 2). Clinically used TCs are characterized by 
a unique C2 amide functionality and one aromatic ring (D 
in Fig. 1), whereas other rings include saturated carbon 
centres (1,3–5). The periphery of the TC molecule can be 
divided into two distinct regions (Fig. 1) designated the 
lower and upper peripheral regions, containing diff erent 
chemical functional groups and substituents. The lower 
peripheral region, which extends from C10 to C4a, is in-
volved in the interaction with the 30S ribosomal subunit 
via the oxygen functional groups on carbon atoms C10-
-C1, and the C2 amide functionality (2). It has been dem-
onstrated that most modifi cations along the lower periph-
eral region of TC greatly decrease antimicrobial activity, 
whereas derivatives modifi ed along the upper peripheral 
region, particularly on positions C7-C9, have demonstrat-
ed greater activity against many diff erent biological tar-
gets (2,4).
Tetracyclines in Clinical Use
CTC, discovered in 1948 by Benjamin Duggar at the 
Lederle Laboratories (later known as American Cyana-
mid, Wayne, NJ, USA), and OTC, discovered in the early 
1950s by Alexander Finlay at Pfi zer (Groton, CT, USA), 
were the fi rst members of the TC group (2). CTC was iso-
lated from Streptomyces aureofaciens, and was named au-
reomycin because of the gold colouring of the bacterial 
culture on agar plates. OTC, on the other hand, is pro-
duced by Streptomyces rimosus and it was isolated in Terre 
Haute, IN, USA, and therefore called terramycin (2). Oth-
er naturally occurring TCs were identifi ed later on, e.g. 
tetracycline from S. aureofaciens, S. rimosus and S. viridofa-
ciens, and the important intermediate 6-demethyl-7-chlor-
tetracycline (demeclocycline, 6DM-CTC), biosynthesized 
by a mutant strain of S. aureofaciens (3). 6DM-CTC is to-
day one of the most important intermediates used at an 
industrial scale in semisynthetic processes for the produc-
tion of second- and third-generation TCs (3,6). TCs alone 
have been the fi ft h most prescribed antibiotics worldwide 
(7). Despite their availability as generic agents and the 
widespread occurrence of resistance by disease agents, 
TCs still have a relatively large market. For example, the 
semisynthetic TC doxycycline has an estimated market of 
over 250 million dollars (8).
Second-generation semisynthetic tetracyclines
The mode of action of TCs consists of their binding to 
the ribosome and inhibiting translation by preventing the 
binding of aminoacylated tRNA to the A site (6). Struc-
tural features within the TC nucleus and the application 
of organic synthetic reactions, investigated independently 
by Lederle and Pfi zer, led to further modifi cations of their 
proprietary tetracycline scaff olds, with the goal of gener-
ating tetracycline antibiotics with improved pharmacoki-
netic properties, increased antimicrobial potency and de-
creased toxicity. Pfi zer chemists modifi ed the C ring of 
OTC (Fig. 1) to produce 6-deoxytetracycline (doxycycline, 
Fig. 2), an analogue with remarkable activity, stability and 
pharmacological effi  cacy, which was approved for use in 
1967 by the USA Food and Drug Administration (FDA) 
(2). Doxycycline is still widely used today, not only for the 
treatment of bacterial infections such as pneumonia, acne, 
chlamydia infections, early lyme disease, cholera and 
syphilis, but also for chemoprophylaxis and treatment of 
malaria. Lederle´s scientists, on the other hand, intensive-
ly studied the biogenesis of CTC mutants in S. aureofaciens 
(2). Among others, they iso lated the precursor 6DM-CTC 
(demeclocycline, Fig. 2), a TC scaff old that possessed 
Fig. 1. Natural tetracyclines produced by diff erent Streptomyces 
species. The upper and the lower peripheral regions of the tet-
racycline backbone are shadowed (2)
Compound R1 R2 R3 R4 R5 R6 R7
TC NH2 N(CH3)2; 4S form H CH3 OH H H
OTC NH2 N(CH3)2; 4S form OH CH3 OH H H
CTC NH2 N(CH3)2; 4S form H CH3 OH Cl H
C6-demethyl-C7-CTC NH2 N(CH3)2; 4S form H H OH Cl H
2-acetyl-2-decarboxy- 
amido-OTC CH3 N(CH3)2; 4S form OH CH3 OH H H
chelocardin CH3 NH2; 4R form H CH3 H H CH3
Fig. 2. Second and third generations of tetracyclines. Omadacy-
cline and eravacycline are currently undergoing clinical evalua-
tion
H. PETKOVIĆ et al.: Biosynthesis of Oxytetracycline by Streptomyces rimosus, Food Technol. Biotechnol. 55 (1) 3–13 (2017) 5
unique C6 and C7 functional groups; further chemical re-
duction of demeclocycline resulted in the industrially im-
portant TC intermediate sancycline (6-demethyl-6-deox-
ytetracycline). Modifi cations of the aromatic D ring using 
semisynthetic approaches produced novel C7 and C9 de-
rivatives of sancycline. Further semisynthetic modifi ca-
tions of sancycline resulted in an analogue possessing a 
7-dimethylamino group, named minocycline (Minocin; 
Fig. 2), whose antibacterial and pharmacological activities 
against a broad range of bacterial pathogens were signifi -
cantly improved, compared to the fi rst-generation com-
pounds and to doxycycline (2,6,9). This improvement can 
be explained by the fact that minocycline has a much 
higher affi  nity for the ribosome than TC and consequent-
ly inhibits in vitro translation more effi  ciently. Thus, mino-
cycline has become one of the most widely used members 
of the TC group (2,6).
Third-generation (semi)synthetic tetracyclines
Due to the increasing incidence of bacterial resistance 
to the fi rst and second generations of TCs, the clinical use 
of tetracyclines has signifi cantly declined in most coun-
tries and in many instances they are no longer drugs of 
choice (3). Thus, in the late 1980s, the increasing pre va-
lence of antibiotic resistance led pharmaceutical compa-
nies, including Wyeth (now Pfi zer), to re-enter or to expand 
their antibiotic discovery programs. Wyeth launched a 
program to further chemically modify the minocycline 
scaff old, producing the fi rst clinical example of a TC that 
is functionalized at the C9 of the D ring (Fig. 2) possessing 
an amide functionality with a glycine subunit att ached 
(2,6). In this way, they generated a series of new ana-
logues for assay and evaluation, referred to as glycylcy-
clines. Many of the compounds were active against Gram-
-positive and Gram-negative bacteria and inhibited both, 
 susceptible and resistant strains (expressing ribosomal 
protection or tetracycline effl  ux proteins), to a similar ex-
tent. Soon, their lead compound tigecycline (9-t-butylgly-
cylamido-minocycline (Tygacyl), Fig. 2) entered clinical 
evaluation and was approved by the FDA for hospital use 
in 2006 (2). Tigecycline displays an affi  nity for the ribo-
some approx. 5-fold higher than that of minocycline (2,6). 
This third-generation TC was the fi rst new one to be intro-
duced into the market in over 40 years. It was specifi cally 
designed to confront tetracycline-resistant mechanisms 
and today it is still clinically active within acceptable min-
imum inhibitory concentration (MIC) ranges against Gram -
-positive isolates obtained globally, including antibiotic- 
-resistant organisms, such as MRSA (methicillin-resistant 
Staphylococcus aureus), vancomycin-resistant enterococci, 
and penicillin-resistant S. pneumoniae (2,6,10,11). How-
ever, due to its potent activity against some Gram-nega-
tive bacteria, it has also become a treatment of last resort 
against multidrug-resistant Gram-negative bacterial patho -
gens (12).
Tetracyclines in the pipeline
By applying transition metal-based semisynthetic 
chem istry to produce tetracycline derivatives, Paratek 
Pharmaceuticals (Boston, MA, USA) developed a 9-ami-
nomethyl aromatic D ring group intermediate of minocy-
cline that was subsequently modifi ed to yield 9-alkylami-
nomethyl minocycline analogues with improved activity 
against a broad spectrum of tetracycline-susceptible and 
resistant bacteria (13,14). One compound, now named 
omadacycline (PTK 0796; Fig. 2) was chosen for its supe-
rior activity, lack of toxicity and oral bioavailability, and it 
is now in phase III clinical trials (2,6,13,14).
On the other hand, a team led by Myers, at Harvard 
University, developed a facile and versatile route to pro-
duce numerous novel TCs at positions that are not bio-
synthetically or semisynthetically amenable (15). This 
unique synthetic approach includes a conjunctive cou-
pling of a BA ring fragment with a D ring precursor (C 
ring is formed in this process), thus generating the TC 
ring system. This pathway for tetracycline synthesis has 
been employed by Tetraphase Pharmaceuticals (Water-
town, MA, USA), leading to the generation of a 7-fl uoro-
tetracycline derivative coded TP-434 (eravacycline, Fig. 2), 
containing 7-fl uoro and 9-pyrrolidinoacetoamido modifi -
cations of D ring (16). Eravacycline was shown to have a 
much higher affi  nity for the ribosome than tetra cycline; it 
consistently inhibits in vitro translation more effi  ciently 
than tetracycline. Eravacycline displays similar ribosome 
binding affi  nity to tigecycline (2,6,16–18). Eravacycline, de-
veloped by Tetraphase Pharmaceuticals, is now in phase 
III clinical trials (19).
Atypical tetracyclines
On the basis of their mode of action, or rather, on the 
basis of their ability to inhibit protein synthesis, TCs can 
be divided into two groups (20). Typical TCs, such as 
OTC, minocycline, doxycycline and tigecycline, comprise 
a group of eff ective protein synthesis inhibitors that bind 
to the 30S ribosomal subunit. On the other hand, a second 
class of TCs has been reported, such as chelocardin (CHD, 
Fig. 3) and anhydrotetracycline, which do not seem to be 
inhibitors of protein synthesis, at least not effi  cient ones, 
thus presenting an opportunity for the development of 
novel TCs with a diff erent mode of action (20). TCs from 
the fi rst group, the so-called typical or classic TCs, display 
a reversible bacteriostatic eff ect, while the atypical TCs 
from the second group lead to a strong bactericidal re-
sponse, most likely by perturbing the organization of the 
bacterial cytoplasmic membrane (3,20,21). CHD, for ex-
ample, is a natural polyketide produced by Amycolatopsis 
sulphurea (22), whereas other atypical TCs are either 
chem ically synthesized as 6-thiatetracycline (23) or shunt 
products in OTC and CTC biosynthesis such as anhy-
drotetracycline, anhydrochlortetracycline and 4-epi an hy-
drochlortetracycline. The mode of action of atypical TCs 
is still to be identifi ed in order to facilitate the develop-
ment of this group of antibiotics. Interestingly, during 
1970s Abbott  (Abbott  Laboratories, Chicago, IL, USA) car-
ried out a phase II clinical trial with CHD in collaboration 
with Dr. Josip Kajfeš hospital (Zagreb, Croatia) for the 
treatment of urinary tract infections (24). However, de-
spite its potent activity against TC-resistant pathogens, 
CHD did not enter the clinic. In recent years, a team led 
by Petković has revisited the biosynthesis of this atypical 
TC analogue, produced by A. sulphurea (25). By applying 
biosynthetic engineering approaches, they have generat-
ed CHD analogues, some of which display potent anti-
bacterial activity against multidrug-resistant pathogens, 
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even against Gram-negative pathogens, which today rep-
resent a great threat in hospitals; they have thus demon-
strated the great potential of atypical TCs (26).
Biosynthetic Pathway of Tetracycline Antibiotics
As described earlier, very productive studies on the 
biosynthesis of CTC, produced by S. aureofaciens, were 
carried out during the 1960s by McCormick et al. (27–35) at 
Lederle. They applied feeding experiments of the blocked 
mutants generated through random mutagenesis, which 
resulted in the production of diff erent TC intermediates 
or shunt products (27–35). The entire biosynthe tic gene 
clusters encoding CTC and OTC (Fig. 4a) were cloned in 
1996 and 1989, respectively (36,37). However, the com-
plete DNA sequence of the gene cluster encoding for OTC 
biosynthesis in the wild type S. rimosus ATCC 10970 strain 
was only published in 2006 by Zhang et al. (38). A number 
of genes involved in the regulation of the OTC and CTC 
gene clusters have also been identifi ed (39,40). Important 
information on the biosynthesis of CTC, particularly re-
lated to the chlorination step in CTC biosynthesis, was 
contributed by Dairi et al. (41) and recent ly described in 
more detail by Zhu et al. (42). However,  the most compre-
hensive studies related to the biosynthesis of TCs were 
carried out on the OTC biosynthetic pathway produced 
by S. rimosus. Therefore, this review predominantly fo-
cuses on the biosynthesis of OTC in S. rimosus.
Early studies on OTC and CTC biosynthesis were 
mostly carried out from the 1960s to the 1980s by research 
groups at Pfi zer (Sandwich, UK), Lederle and Pliva (Za-
greb, Croatia). Very productive work on the genetics of 
TC-producing strains, as well as on the biosynthesis of 
CTC and OTC was carried out by academic groups in the 
former Czechoslovakia and by Croatian researchers at the 
Faculty of Food Technology and Biotechnology at the 
University of Zagreb (43). Russian scientists from the All-
-Union Research Institute for Antibiotics in Moscow also 
contributed to the area of genetics of OTC production by 
S. rimosus; their work was mostly published in Russian 
journals (44). Early circular chromosomal linkage maps of 
three S. rimosus strains with nutritional markers and S. 
rimosus mutants, blocked in OTC production, were inde-
pendently constructed by two research groups, as report-
ed by Friend and Hopwood (45) in the UK, and by 
Alačević et al. (46–49) in Zagreb. Analysis of non-OTC- 
-producing mutants initially suggested the position of 
some loci responsible for the biosynthesis of OTC in the 
Fig. 3. Selected aromatic polyketide metabolites displaying diverse biological activities. Their corresponding gene clusters present 
rich source of biosynthetic enzymes, which can be readily used in biosynthetic engineering approaches for the generation of new 
derivatives
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lower arc of the map. Interestingly, these studies were 
pointing to two locations of the genes involved in OTC 
biosynthesis on the physical map of the S. rimosus chro-
mosome (46–49).
At the beginning of the 1980s, the Pfi zer group pub-
lished advanced genetic and biochemical studies based 
on S. rimosus mutants that were impaired in their OTC 
biosynthesis (50). However, following the advent of mo-
lecular biology approaches during the early 1980s, and 
very importantly, knowing that genes involved in second-
ary metabolite biosynthesis are most oft en clustered in a 
single location, the researchers at Pfi zer managed to clone 
the entire gene cluster encoding for the biosynthesis of 
OTC (51,52) (Fig. 4a). Subsequently, they managed to het-
erologously express the entire OTC gene cluster in Strep-
tomyces lividans and Streptomyces albus, thus resulting in 
the production of OTC in heterologous hosts. This was a 
remarkable achievement (37,53) and it was thus con-
fi rmed that the entire OTC biosynthetic pathway, of 
around 35 kb in size, is located in a single location on the 
S. rimosus chromosome. These eff orts were later on fol-
lowed by collaborative research between Hunter’s group 
in Glasgow (UK) (54) and a research group in Zagreb 
(Croatia) working at the pharmaceutical company Pliva 
(55,56).
However, during th e last decade, the most signifi cant 
insight into OTC biosynthesis has been gained by Tang´s 
research group at the University of California, Los Ange-
les (USA) (57–63).
Initiatio n steps in TC biosynthesis
The polyketide skeleton of TCs is synthesized by type 
II minimal polyketide synthase (minimal PKS) genes 
(64,65), consisting of ketosynthase α, ketosynthase β and 
acyl carrier protein (ACP), designated as OxyA, OxyB 
and OxyC in OTC biosynthesis, respectively (Fig. 4) (4). 
Although the exact mechanism of initiation in OTC bio-
synthesis is not well understood yet, the initial steps in 
OTC biosynthesis are carried out by a so-called minimal 
PKS consisting of two ketosynthase units KS and KS, 
an ACP (OxyABC), an amidotransferase (AMT), OxyD 
Fig. 4. Schematic presentation of: a) the gene cluster encoding for OTC biosynthesis from S. rimosus. The enzymatic activity of each 
putative gene is marked with diff erent symbols and corresponds to the legend. The function of each gene product in the OTC gene 
cluster (in a) corresponds to the proposed OTC biosynthetic pathway (in b); and b) the biosynthetic pathway of oxytetracycline 
(OTC) and chlortetracycline (CTC), based on the biosynthetic gene clusters of OTC and CTC from S. rimosus and S. aureofaciens, re-
spectively. The position on the tetracycline backbone of each proposed tetracycline precursor modifi ed by the corresponding enzyme 
from the OTC (CTC) enzyme complex at each proposed biosynthetic step is shadowed. For colour version see: www.ft b.com.hr
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(catalysing the transamination reaction of malonate to 
malonamate) and a putative acyltransferase (AT) homo-
logue, OxyP (61) (Fig. 4). The function of the AT domain 
in OTC biosynthesis is not yet fully understood. Interest-
ingly, inactivation of oxyP gene did not abolish the bio-
synthesis of OTC, but it did increase the proportion of 
2-acetyl-2-decarboxyamido-oxytetracycline (ADOTC), com-
pared to OTC (61) (Fig. 1).
In contrast to the studies on the priming in OTC bio-
synthesis, Lešnik et al. (26) recently demonstrated that 
OxyP from the OTC gene cluster actually plays an essen-
tial role in the selection of an unusual malonamate starter 
unit when heterologously expressed in A. sulphurea. Hete-
rologous expression of AT homologue oxyP gene, together 
with oxyD, resulted in the formation of a hybrid analogue 
of CHD, containing a carboxyamido group at C2 position, 
the 2-carboxyamido-2-deacetyl-chelocardin (CDCHD, Fig. 
3). Thus, the hybrid structure CDCHD is effi  ciently pro-
duced by the recombinant strain of A. sulphurea only if 
both, AMT and AT, are heterologously expressed. Inter-
estingly, in the biosynthesis of the tricyclic aromatic poly-
ketide compound R1128 (Fig. 3), produced by Streptomy-
ces sp. R1128 (66), Tang et al. (67) demonstrated that the 
OxyP homologue ZhuC, from the R1128 gene cluster, dis-
plays thioesterase activity. Therefore, these authors have 
suggested that AT in R1128 biosynthesis is in fact a proof-
reading enzyme, involved in the removal of inappropri-
ate starter units from minimal PKS that might block the 
enzymatic complex. However, the function of the oxyP 
gene and the choice of starter unit in OTC biosynthesis 
are not yet fully understood.
Formation of the tetracycline backbone in OTC 
biosynthesis
The chemical structure of TCs implies that they are 
aromatic polyketides synthesized by a type II polyketide 
synthase (PKS) (64,65). As discussed earlier, polyketide 
assembly from malonate-derived building blocks is 
achieved by iterative Claisen-like condensations, cata-
lyzed by the minimal PKS, consisting of the ketosynthase 
(KSα), its cognate homologue KSβ (without an active site 
cysteine), also designated as chain length factor (CLF) 
(68), and a co gnate ACP. The minimal PKS enzymes cata-
lyze the iterative Claisen-like condensation of the starter 
unit, most likely malonamyl-CoA, and eight extender ma-
lonyl-CoA units, resulting in nascent amidated decaketide 
backbone (1 in Fig. 4b). It was proposed that malonyl- 
-CoA:ACP acyltransferase, which transfers the extender 
unit malonyl-CoA to ACP, can be shared with fatt y acid 
biosynthesis (69). Initial folding of the growing polyketide 
chain is directed by a ketoreductase OxyJ, which catalyses 
the region-specifi c reduction of the keto group at C8 
(chemical nomenclature in Fig. 1, and 2 in Fig. 4b) (54). 
Crucial biosynthetic steps of cyclisation and aromatiza-
tion result in the formation of the basic tetracyclic struc-
ture of all TCs (Fig. 1). Key steps in closure and aromati-
sation of the fi rst ring (D) (3 in Fig. 4b), catalysed by 
two-component cyclase/aromatase OxyK, are likely oc-
curring rapidly with the C8 keto group reduction (54). 
Petković et al. (54) have demonstrated that in S. rimosus 
the cyclase/aromatase gene otcD1 (designated as oxyK by 
Zhang et al. (57), Fig. 4a) plays a key role in the formation 
of the fi rst ring, considering that inactivation of otcD1 
gene results in an aberrant cyclisation patt ern of the nas-
cent polyketide chain. Interestingly, inactivation of otcD1 
also derailed the functionality of the minimal PKS com-
plex, resulting in the formation of a number of com-
pounds of various chain lengths consisting of 9, 15 or 17 
carbon atoms (54). Remarkably, all these compounds con-
tain a carboxyamido moiety, giving a strong indication 
that addition of the amino group does not happen aft er 
the formation of the basic TC backbone, a possibility that 
was considered in the early days. Subsequently, Zhang et 
al. (57) also confi rmed the function of OxyK (OtcD1) as a 
cyclase/aromatase.
The formation and aromatisation of the fi rst ring (D) 
is followed by the closure of the second ring (C), most 
likely catalysed by the mono-domain cyclase OxyN; the 
closure of the third ring (B) is believed to be spontaneous 
(4 in Fig. 4b) (58,59). Last ring (A) formation, resulting in 
the fi rst stable tetracyclic intermediate pretetramide (5 in 
Fig. 4b), was at fi rst suggested to be catalysed by the third 
group of OxyI cyclases (58). However, it was later pro-
posed that the closure of the fi nal ring of OTC is sponta-
neous, because of the presence of the terminal amino 
group (58). To date, the function of the OxyI cyclase has 
not been elucidated; nevertheless, it is possible that OxyI 
still facilitates the formation of the last (A) ring (Fig. 4b).
It was originally proposed that the oxyH gene, present 
in the OTC gene cluster, is involved in the activation of 
the starter unit, being thus involved in the priming steps 
of OTC biosynthesis. OxyH homologues were also found 
in the CTC (42), mithramycin (70), SF2527 compound (71) 
and polyketomycin (72) gene clusters. The role of the 
acyl-CoA-ligase SsfL2, homologous to OxyH from the oxy 
gene cluster, putatively involved in the formation of the 
fourth ring of the TC-like compound SF2527 was dis-
cussed by Pickens et al. (71). Interestingly, the OxyH was 
demonstrated by gene-inactivation studies to be dispen-
sable: therefore, its function is not yet understood (4). 
Considering that the cyclisation steps in TC biosynthesis 
occur between enzymatically catalysed reactions and 
spontaneous chemically-driven reactions, it is not surpris-
ing that the mechanism of cyclisation is not yet fully un-
derstood.
Based on the studies carried out using blocked mu-
tants (27–35), the fi rst stable OTC intermediate is likely 
the fully aromatised tetracyclic compound called prete-
tramide (5 in Fig. 4b), which then undergoes further 
processing, tailoring reactions of the fully formed TC 
backbone; this is also called post-PKS tailoring.
Tailoring reactions of the basic tetracycline backbone
A large enzyme complex designated as type II PKS, 
where a number of independent enzymes likely cooper-
ate simultaneously, carries out the formation of OTC. 
Thus, when considering the biosynthetic pathway in-
volved in the formation of TCs, it is probably not appro-
priate to defi ne the biosynthetic steps as a number of or-
dered reactions. However, based on numerous OTC and 
CTC intermediates or shunt products isolated from 
blocked mutants of S. rimosus and S. aureofaciens, respec-
tively (27–35), it is possible to speculate on the preferred 
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order of enzymatic reactions involved in the modifi cation 
of the early TC intermediate pretetramide (5 in Fig. 4b). 
Considering that the methyl group at carbon C6 is found 
in almost all early intermediates in the biosynthesis of 
OTC and CTC, when blocked mutants were analysed at 
Lederle (27–35), it was believed that methylation by me-
thyl-transferase OxyF at the C6 position is one of the ear-
liest steps in the tailoring reactions of the TC backbone (6 
in Fig. 4b) (58). However, the isolation of the blocked S. 
aureofaciens mutant by Ryan (73), producing 6-demethyl- 
-CTC, confi rms that methylation at C6 is not obligatory as 
the earliest step in the modifi cation of the pretetramide. 
Hence, it is likely the most preferred route (30,74). The C6 
methylation is probably followed by a double hydroxyla-
tion of ring A at C4/C12a by oxygenase pairs OxyL in 
OxyE, whereas OxyE is believed to be an ancillary mono-
oxygenase for OxyL with a nonessential but important 
role in improving its catalytic effi  ciency as a C4 hydroxy-
lase (7 and 8 in Fig. 4b) (60). Hydroxylation at C4 is a pre-
requisite for the incorporation of an amino group at C4 by 
PLP-dependent aminotransferase OxyQ (9 in Fig. 4b), 
which is followed by dimethylation of the amino group 
by N,N-dimethyltransferases OxyT, to yield anhydrotet-
racycline (ATC) (10 in Fig. 4b) (59). Hydroxylation of ATC 
at C6 is catalysed by FAD-dependent monooxygenase 
OxyS (11 in Fig. 4b). Interestingly, OxyS has recently been 
found responsible also for the hydroxylation of C5 in the 
biosynthesis of OTC (14 in Fig. 4b) (63). An earlier obser-
vation by Perić-Concha et al. (55) that the deletion of the 
otcC gene (designated as oxyS by Zhang et al. (57)) result-
ing in the production of a tricyclic compound containing 
17 carbon atoms was rather surprising. Perić-Concha et al. 
(55) demonstrated that even the enzyme involved in the 
late stages, the so-called post-PKS processing, can interact 
with minimal PKS, thus infl uencing the ability of the min-
imal PKS to make a polyketide of the correct chain length. 
As suggested by Wang et al. (63), the last step in OTC bio-
synthesis is believed to be the reduction of the C5a−C11a 
double bond by OxyR, to yield OTC (15 and 12 in Fig. 4b 
in CTC biosynthesis) (63). In the CTC biosynthesis, the 
halogenation as the fi nal step occurs at the C7 position (13 
in Fig. 4b). As expected, chlorination in the CTC biosyn-
thetic pathway, a step that is not encoded in the OTC gene 
cluster, is catalysed by the fl avin-dependent halogenase 
CtcP (13 in Fig. 4b) (42).
Regulation of tetracycline biosynthesis and genes 
involved in resistance
Environmental factors, such as carbon, nitrogen, in-
organic phosphate, metal ion and other nutrient sources, 
cultivation condition parameters, such as pH and aera-
tion (dO2), and cultivation methods in general, may aff ect 
the timing and the extent of TC production (43,75,76). Me-
dia containing high concentrations of starch as a carbon 
source are generally used in fermentation processes for 
the production of OTC with S. rimosus at the industrial 
level, although vegetable oil can also be used as a carbon 
source. It was shown that S. rimosus produces OTC abun-
dantly when subjected to phosphate starvation (43,75,76). 
McDowall et al. (77) reported that the sequences of the 
promoter regions in the S. rimosus 4018 strain (now desig-
nated as DNA sequence encoding oxyI, oxyJ, oxyR, oxyS 
and oxyA genes (40)) contain tandem repeats that are sim-
ilar to the DNA-binding sites of Streptomyces antibiotic 
regulatory protein (SARP) transcription activators. They 
suggested that OTC production by S. rimosus requires a 
SARP-like transcription factor that is either produced 
and/or activated when phosphate concentrations are low 
(77). Just recently, Yin et al. (40) identifi ed a SARP-like 
regulator, OtcR, located immediately adjacent to the resis-
tance gene otrB (Fig. 4a). OtcR acts as a positive pathway-
-specifi c activator of OTC biosynthesis, which leads to a 
signifi cant increase in OTC production when overex-
pressed at the appropriate level. Based on amino acid se-
quence analyses, OtcR and Ctc11 (CtcB) from S. aureofa-
ciens share 46 % identity; furthermore, the predicted 
SARP-binding sites were also identifi ed in the ctc cluster. 
Interestingly, Wang et al. (62) found that the SARP regula-
tor, encoded by ctc11 (ctcB) from the CTC gene cluster 
(ctc) of S. aureofaciens (36), could activate the transcription 
of the oxy cluster in the heterologous host Streptomyces co-
elicolor (62). Since OTC and CTC are structurally highly 
similar antibiotics, it is reasonable to expect similar bio-
synthetic and regulatory mechanisms. The second regula-
tory element OtcG was identifi ed by Lešnik et al. (39). 
OtcG belongs to the LAL (LuxR) family of transcriptional 
regulators and it is located on the other side of the otc 
gene cluster, in the vicinity of the otrA resistance gene 
(Fig. 4a). OtcG plays a conditionally positive role in OTC 
biosynthesis, considering that inactivation of the otcG 
gene in the S. rimosus 4018 strain reduces the production 
of OTC by more than 40 %. However, overexpression of 
otcG by introducing a second copy of the gene under the 
strong constitutive promoter ermE* did not yield any sta-
tistically signifi cant change in the production of OTC (39). 
To conclude, to date two regulatory proteins, OtcG and 
OtcR, have been identifi ed in the gene cluster encoding 
OTC biosynthesis in the S. rimosus 4018 strain.
Interestingly, three genes encoding resistant determi-
nants (otr), designated otrA, otrB and otrC, have been 
identifi ed in S. rimosus (78,79). OTC is a bacteriostatic an-
tibiotic that inhibits bacterial growth by reversibly bind-
ing to the 30S ribosomal subunit and preventing the for-
mation of the aminoacyl-tRNA–ribosome complex. OtrA 
protects the ribosome from translational arrest by TCs 
(80–82). The otrA, located in the right fringe of the OTC 
gene cluster, is a paralogue found in pathogens that cause 
tetracycline-resistant clinical infections (encoded by tetO 
and tetM). These proteins are similar to elongation factors 
and act by releasing tetracyclines from their inhibitory 
site on the ribosome (80). The second gene, otrB, encodes 
an integral membrane protein that is responsible for the 
effl  ux of OTC from the cell (80,83,84). Interestingly, this 
gene is regulated by another regulatory type protein, the 
putative MarR family repressor protein OxyTA1 (also 
designated in the past as OtrR (79)). The oxyTA1 has been 
identifi ed in the OTC gene cluster, which is divergently 
transcribed from the resistance gene otrB (3). Thus, the 
overall topology of the otrB-oxyTA1 region mirrors that 
found in Tn10, with the expression of the tetracycline ef-
fl ux pump being controlled by a divergent repressor 
(78,83). Finally, the otrC gene, which is not part of the otc 
gene cluster, is only ensuring a lower level of resistance 
against OTC (85). Yu et al. (85) have presented evidence in 
their recent publication indicating that otrC encodes a 
protein with ATPase and multidrug effl  ux activity.
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Future Directions in Biosynthetic Engineering of 
Tetracycline Analogues
As demonstrated by Charest et al. (15) and Sun et al. 
(17), who applied synthetic chemistry approaches, it is 
possible to envisage an entirely new synthetic route to-
wards developing unique TC analogues, thus evading the 
established semisynthetic routes used in the development 
of the third generation of TCs. Similarly, biosynthetic en-
gineering approaches also off er new routes. Early work at 
the Lederle laboratories resulted in the production/isola-
tion of the extremely valuable TC precursor 6DM-CTC 
(27–37,73). By applying random mutagenesis approaches, 
numerous tetracycline analogues have been isolated from 
the cultures of S. aureofaciens and S. rimosus mutant strains 
(reviewed by Vanĕk and Hoštálek in 1986 (86)). However, 
despite the early success by McCormick’s team at Lederle 
(27–35), and a much deeper understanding of TC biosyn-
thesis gained over the last decades, a relatively limited 
number of new TC analogues have been reported to date 
in the literature. This is likely due to a general lack of in-
terest in anti-infective drug development (87). In addi-
tion, relatively slow and tedious molecular biology ap-
proaches for the genetic manipulation of TC-producing 
actinobacteria have likely contributed to the relatively 
low success of the applied biosynthetic engineering ef-
forts. However, aff ordable and versatile biosynthetic en-
gineering and synthetic biology approaches, which have 
rapidly evolved in the recent years, will signifi cantly fa-
cilitate any potential biosynthetic eff orts directed towards 
producing new TC scaff olds. The reiterative nature of the 
type II PKS enzymatic machinery, catalyzing the biosyn-
thesis of TCs, does not off er such diverse number of ap-
proaches to biosynthetic engineering routes compared to 
the type I PKS system, represented by the modular PKS 
systems involved in e.g. macrolactone biosynthesis (88). 
However, biosynthetic engineering eff orts in TCs are not 
exhausted, and can be productively applied at the initial 
steps of TC biosynthesis (e.g. starter unit selection) as well 
as at the late stages of TC biosynthesis, the so-called post-
-PKS processing, steps that are oft en of crucial importance 
for the biological activity of these compounds (26,62). A 
number of TC structures with a broad range of biological 
activities have been isolated (Fig. 3) and the correspond-
ing gene clusters have been cloned, as recently exempli-
fi ed by Wang et al. (62) and Lukežič et al. (25).
Rational biosynthetic engineering approaches repre-
sent at present a valuable complementary strategy to the 
existing semisynthetic approaches. Novel functional 
groups, identifi ed in the scope of DNA sequencing strate-
gies, can be introduced into the established TC scaff olds 
(e.g. CTC or OTC). However, the reverse approach, 
whereby functional group(s) found in clinically-used TC 
analogues, such as OTC or CTC, are introduced into nov-
el TC scaff olds using biosynthetic engineering approach-
es, might as well be a valuable alternative. For example, 
the C2-carboxyamido moiety, found in typical tetracy-
clines such as OTC and CTC, is known to be an important 
structural feature for their bioactivity (2,4). Applying the 
latt er strategy, Lešnik et al. (26) introduced the C2-car-
boxyamido moiety found in typical tetracyclines into the 
CHD backbone. This was achieved through the expres-
sion of the amidotransferase OxyD, catalysing the trans-
amination reaction of malonate to malonamate, and an 
acyltransferase homologue OxyP, both involved in the 
priming steps in the OTC pathway from S. rimosus in 
CHD-producing strain A. sulphurea. The recombinant 
strain constructed this way resulted in the effi  cient pro-
duction of a new analogue with signifi cantly improved 
antibacterial activity (26).
A number of non-commercial TC analogues of bacte-
rial or fungal origin are known, whose biosynthetic path-
ways have been studied, such as SF2575 produced by 
Streptomyces sp. SF2575 (71), dactylocycline produced by 
Dactylosporangium sp. SC14051 (62), and CHD produced 
by A. sulphurea (25). Other structurally related tetracyclic 
secondary metabolites reported in the literature and pro-
duced by actinobacteria include cervimycin C produced 
by Streptomyces tendae HKI-179 (89), polyketomycin pro-
duced by Streptomyces diastatochromogenes Tü6028 (72) and 
dutomycin, isolated from the culture of Streptomyces sp. 
1725 (90) (Fig. 3). As exemplifi ed by Wang et al. (62), rap-
idly expanding genomics data, available in the recent 
years thanks to signifi cantly improved and aff ordable 
DNA sequencing technologies, will undoubtedly result in 
the identifi cation of numerous novel gene clusters encod-
ing for the production of TC scaff olds.
Conclusion
Despite the much deeper understanding gained over 
the last two decades on tetracycline biosynthesis, biosyn-
thetic approaches to the development of TC antibiotics 
have not been productive. However, recent development 
of rapid and powerful molecular biology tools for the ma-
nipulation of TC pathways in antibiotic-producing 
strains, and rapidly expanding genomics data available 
today will undoubtedly augment the capacity of the bio-
synthetic engineering and semisynthetic eff orts applied 
for the development of novel TC antibiotics.
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